Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights pragmatic randomized trials and large cohort/consensus work that shift perioperative risk management and perioperative optimization. Key trials support higher intraoperative MAP targets in hypertensive high-risk abdominal surgery to reduce organ dysfunction, and intraoperative dexmedetomidine to markedly improve early postoperative sleep in older adults. Large multi-cohort data integrate biological age (PhenoAge) into perioperative risk stratifica
Summary
This week’s anesthesiology literature highlights pragmatic randomized trials and large cohort/consensus work that shift perioperative risk management and perioperative optimization. Key trials support higher intraoperative MAP targets in hypertensive high-risk abdominal surgery to reduce organ dysfunction, and intraoperative dexmedetomidine to markedly improve early postoperative sleep in older adults. Large multi-cohort data integrate biological age (PhenoAge) into perioperative risk stratification, enabling precision prehabilitation beyond chronological age.
Selected Articles
1. HIgh versus STAndard blood Pressure target in hypertensive high-risk patients undergoing elective major abdominal surgery: the HISTAP multicenter randomized clinical trial.
In a multicenter randomized trial of 630 hypertensive, high-risk adults undergoing major abdominal surgery, targeting intraoperative MAP ≥80 mmHg versus ≥65 mmHg reduced a composite of postoperative mortality and major organ dysfunction (RR 0.78) and reduced acute kidney injury, achieved under protocolized fluids and continuous monitoring.
Impact: This pragmatic, multicenter RCT directly informs intraoperative hemodynamic targets for a common high-risk surgical population and demonstrates clinically meaningful organ-protective effects, especially for the kidney.
Clinical Implications: Consider targeting a higher intraoperative MAP (≥80 mmHg) in hypertensive high-risk patients undergoing major abdominal surgery with continuous hemodynamic monitoring and protocolized fluid/vasopressor strategies, balancing vasopressor exposure against organ-protection benefits.
Key Findings
- Primary composite outcome lower with MAP≥80: 38.1% vs 48.9% (RR 0.78; 95% CI 0.65–0.93; P=0.006).
- Acute kidney injury reduced in MAP≥80 group (23.5% vs 33.7%; P=0.005).
- Achieved mean intraoperative MAP separation (88±9 vs 77±7 mmHg) under protocolized care.
2. Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery: a single-center, randomized, double-blind, placebo-controlled trial.
A randomized, double-blind trial of 210 older adults found intraoperative dexmedetomidine infusion (0.3 or 0.6 μg/kg/h) reduced first-night postoperative sleep disturbance by ~70–80% versus saline (NNT ≈2), improved night-2 sleep and early recovery quality, without increasing hypotension, bradycardia, delirium, or 30-day mortality.
Impact: High-quality RCT demonstrating a widely available sedative can substantially improve early postoperative sleep—a modifiable recovery factor linked to outcomes—providing an immediately actionable perioperative strategy.
Clinical Implications: Consider low-dose intraoperative dexmedetomidine infusion to reduce early postoperative sleep disturbance in older adults undergoing major abdominal surgery, with routine hemodynamic monitoring; multicenter validation and assessment of downstream cognitive outcomes are recommended.
Key Findings
- Both 0.3 and 0.6 μg/kg/h reduced first-night PSD versus saline (relative risk reductions ~69% and ~82%).
- Improved night-2 sleep metrics and QoR-15 on POD1; actigraphy subset showed longer total sleep time.
- No increase in hypotension, bradycardia, delirium, or 30-day mortality across groups.
3. Biological aging increases risk of postoperative morbidity and mortality: an international, multi-cohort study.
Across >430,000 surgical patients in international cohorts, the biological age metric PhenoAge independently predicted 1-year mortality, major cardiovascular events, and 30-day readmission beyond chronological age, frailty, comorbidity, ASA, and surgical complexity; findings were replicated in three cohorts and prospectively validated for early complications.
Impact: Integrates a scalable biological aging metric into perioperative prognostication with external replication and prospective validation, enabling precision gerisurgery and targeted prehabilitation irrespective of chronological age.
Clinical Implications: Calculate PhenoAge from routine lab data to identify 'fast agers' who may benefit from intensified prehabilitation and enhanced perioperative monitoring; incorporate PhenoAge into multidisciplinary shared decision-making for complex procedures.
Key Findings
- PhenoAge independently predicted 1-year mortality (UK Biobank OR 1.043; p<0.001), major adverse cardiovascular events, and 30-day readmission after adjustment.
- Fast Agers had a ~49% higher mortality risk than Normal Agers.
- Results replicated across MOVER, Weill Cornell, and INSPIRE cohorts and prospectively validated for 3-day complications (OR 1.20; p=0.015).